Difficulty: Medium
Average Score: 67%
Practice
Which one of the following agents is implicated in causing cutaneous lupus?
Correct answer
B
Rationale
In the context of pediatric nursing and dermatology, understanding the implications of different medications on conditions like cutaneous lupus is crucial. In this case, the correct answer is B) sulfonamide. Sulfonamides have been identified as a trigger for drug-induced cutaneous lupus erythematosus. This particular medication has been linked to the development of lupus-like symptoms in some individuals.
Regarding the incorrect options:
A) Corticosteroids are commonly used in the treatment of lupus to reduce inflammation and suppress the immune response. They are not known to cause cutaneous lupus.
C) Allopurinol is a medication used to treat gout and kidney stones, and it is not associated with causing cutaneous lupus.
D) Beta-lactam antibiotics, such as penicillin, cephalosporins, and others, are not typically implicated in causing cutaneous lupus.
Educationally, this question highlights the importance of medication knowledge and its potential effects on pediatric patients with autoimmune conditions like lupus. It emphasizes the need for healthcare providers to be aware of potential triggers for cutaneous lupus and to consider medication histories when managing these patients. Understanding these associations can guide clinical decision-making and promote safe and effective care for pediatric patients with autoimmune disorders.
Regarding the incorrect options:
A) Corticosteroids are commonly used in the treatment of lupus to reduce inflammation and suppress the immune response. They are not known to cause cutaneous lupus.
C) Allopurinol is a medication used to treat gout and kidney stones, and it is not associated with causing cutaneous lupus.
D) Beta-lactam antibiotics, such as penicillin, cephalosporins, and others, are not typically implicated in causing cutaneous lupus.
Educationally, this question highlights the importance of medication knowledge and its potential effects on pediatric patients with autoimmune conditions like lupus. It emphasizes the need for healthcare providers to be aware of potential triggers for cutaneous lupus and to consider medication histories when managing these patients. Understanding these associations can guide clinical decision-making and promote safe and effective care for pediatric patients with autoimmune disorders.